Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.
about
Albumin-based drug delivery: harnessing nature to cure diseaseA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsAlbiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiencyOnce-weekly albiglutide in the management of type 2 diabetes: patient considerations.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Association of pancreatitis with glucagon-like peptide-1 agonist use.Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesEfficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosingGlucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes.Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.Incretin-based therapies.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Emerging GLP-1 receptor agonists.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.GLP-1 based therapies: differential effects on fasting and postprandial glucose.Drug development: longer-lived proteins.Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.Albiglutide: a review of its use in patients with type 2 diabetes mellitus.Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.Controlled release of biologics for the treatment of type 2 diabetes.Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.Half-life extended biotherapeutics.Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).Bioconjugation - using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers.Albiglutide: a unique GLP-1 receptor agonist.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.
P2860
Q26765789-A73C723C-2293-4F98-987C-CA46E3B13246Q26799389-28EA1751-12B9-43CB-B93D-3BAD8C8AFF6BQ28077026-91BB96F8-50A7-42C4-9EFA-6602687D3796Q28740948-087ED10B-6EEB-4125-816C-EF6630911A7EQ33728226-EA899FC4-CFEB-482F-94DC-07075397E101Q33786150-8878F862-3F82-4A68-9DBE-3174D6D28E6FQ34618507-BFB98E8B-8F9A-411E-B755-C1E98372458BQ35087846-E68E17D6-00AF-4B0B-A526-C6E9056C0976Q35671396-B94F2E31-7E35-4C05-BF46-BC96EC31D2EEQ35684362-B90B8EE7-7BE2-4302-B21C-4201F9A8BCA7Q35909303-A843277D-1943-4628-AC9F-0C0C7D6350DDQ36441684-EA01DDD6-6581-4BB0-B906-75C4298CEFA9Q37316259-1EDAD019-06CD-4D6A-ABE5-8F5220DB4ED7Q37340223-13D85874-56AA-48F3-8003-DB415ACE6D77Q37364896-C507D96C-4E05-44D0-B3FC-3AFD12385326Q37402786-E9E65869-BB19-4534-AF22-64C690B6A2B2Q37410215-A7C1BA58-4087-413C-AAB8-84D51B9C00D5Q37556648-C4D1B3AB-255A-46C6-9754-150C596B65D4Q37682561-F2C1D5B5-A26E-4134-BCE8-3062622AE577Q37724230-0A68AEFA-B6C7-48A0-B60C-CE7F3C74EBEAQ37852801-02A82B44-A7B6-4B6C-88EA-3D694A065D6EQ37894864-42F1AB08-AB7A-4FAD-B307-E26E61FB0187Q37929159-E26556F3-D75B-4BE5-AF78-6E89C5DE2843Q37929744-9AE1A31D-7AF8-4F28-9848-07C3F0448730Q37941683-0FC188BD-0C1D-4742-AE48-F3E7CF35103AQ37974632-0D4B65AB-10A9-47A9-840D-44CFD382A3BDQ37974712-BE12A997-7490-45D5-A57D-C413996E8D82Q37981866-52106F73-041F-40C8-BB88-181C8E39091BQ38234927-5E2B6165-E3C6-4B52-AC5F-9A437FFA68CEQ38241171-ED9EB6F0-D840-4072-A586-A238D8E39E42Q38267138-6F07655E-AB80-4321-801B-45719E937CBDQ38380559-4548FBEE-6014-4053-A695-709370D84627Q38542098-5B599CD5-84F9-4F72-9404-1C5F075D8E41Q38665753-B4F0A795-A092-4EFC-9591-92B752461F88Q38690867-9A4B379F-8A22-4FDC-924E-4EF33794060DQ38770067-5CE6DE8F-D074-4410-B11A-1D8D2D636E7EQ38838461-E38A3320-CDCF-4F6E-8DC3-B101134EE51FQ38909537-0674FD9B-3976-47C9-81A7-4F453CC47718Q38966029-BAF91244-3E2E-4248-8A44-FE28F3463168Q38989309-41F3F0D9-315B-4499-BA00-BA88AAE9ADF2
P2860
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Safety, tolerability, pharmaco ...... mimetic, in healthy subjects.
@ast
Safety, tolerability, pharmaco ...... mimetic, in healthy subjects.
@en
type
label
Safety, tolerability, pharmaco ...... mimetic, in healthy subjects.
@ast
Safety, tolerability, pharmaco ...... mimetic, in healthy subjects.
@en
prefLabel
Safety, tolerability, pharmaco ...... mimetic, in healthy subjects.
@ast
Safety, tolerability, pharmaco ...... mimetic, in healthy subjects.
@en
P2093
P1476
Safety, tolerability, pharmaco ...... mimetic, in healthy subjects.
@en
P2093
E H De Boever
J E Matthews
M C Holland
M Gutierrez
M W Stewart
R L Dobbins
S E Walker
P2860
P304
P356
10.1111/J.1463-1326.2008.00992.X
P577
2008-02-11T00:00:00Z